Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 7/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15849827 | 1.00 | HDAC8 (0.45) | HDAC8EGFRFAAHABCG2MEN1 | |
| SCHEMBL13820229 | 1.00 | HDAC8 (0.45) | HDAC8EGFRFAAHABCG2MEN1 | |
| SCHEMBL13827424 | 0.93 | HDAC8 (0.48) | HDAC8FAAHHDAC2CYP17A1 | |
| SCHEMBL18069670 | 0.84 | ABCG2 (0.41) | HDAC8ABCG2KMT2ALMNA | |
| SCHEMBL21100864 | 0.84 | FAAH (0.44) | FAAHABCG2 | |
| SCHEMBL17919158 | 0.84 | FAAH (0.44) | FAAHABCG2 | |
| SCHEMBL26079041 | 0.84 | HDAC8 (0.46) | HDAC8FAAHCYP17A1PTPN11 | |
| SCHEMBL22006732 | 0.83 | APP (0.52) | FAAHMEN1KMT2ACYP17A1LMNA | |
| SCHEMBL15731128 | 0.83 | APP (0.52) | FAAHMEN1KMT2ACYP17A1LMNA | |
| SCHEMBL24220444 | 0.82 | CA12 (0.46) | FAAHMEN1KMT2ACYP17A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2823826-A2 | Inhibitors of carbonic anhydrase IX | Molecular Insight Pharmaceuticals, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8877970-B2 | Inhibitors of carbonic anhydrase IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877970-B2 | Inhibitors of carbonic anhydrase IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| WO-2009089383-A2 | INHIBITORS OF CARBONIC ANHYDRASE IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | CA9, CA12, CA1 | HDAC8 83/4885EGFR 1119/4885FAAH 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.